Merus N.V. is a clinical-stage biotechnology company headquartered in Utrecht, the Netherlands, focused on developing multispecific antibody therapeutics for oncology. The company’s proprietary Biclonics and Triclonics platforms generate full-length human bispecific and trispecific antibodies designed to target tumor-associated pathways and engage the immune system.
Merus’ pipeline includes zenocutuzumab (MCLA-128), which targets HER2/HER3, and petosemtamab (MCLA-158), which targets EGFR/LGR5, along with additional investigational candidates in earlier development. The company conducts global clinical studies and maintains research and development operations in Europe and the United States. Merus is listed on Nasdaq under the ticker MRUS.